Linden Thomas Advisory Services’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $842K | Buy |
6,699
+96
| +1% | +$12.1K | 0.09% | 322 |
|
|
2025
Q1 | $730K | Buy |
6,603
+253
| +4% | +$28K | 0.09% | 327 |
|
|
2024
Q4 | $867K | Buy |
6,350
+289
| +5% | +$39.4K | 0.11% | 307 |
|
|
2024
Q3 | $698K | Buy |
6,061
+265
| +5% | +$30.5K | 0.1% | 329 |
|
|
2024
Q2 | $798K | Sell |
5,796
-972
| -14% | -$134K | 0.12% | 299 |
|
|
2024
Q1 | $933K | Buy |
6,768
+312
| +5% | +$43K | 0.15% | 274 |
|
|
2023
Q4 | $851K | Buy |
6,456
+225
| +4% | +$29.6K | 0.16% | 261 |
|
|
2023
Q3 | $701K | Sell |
6,231
-9,302
| -60% | -$1.05M | 0.16% | 275 |
|
|
2023
Q2 | $1.46M | Buy |
15,533
+138
| +0.9% | +$13K | 0.33% | 106 |
|
|
2023
Q1 | $1.56M | Buy |
15,395
+371
| +2% | +$37.6K | 0.39% | 88 |
|
|
2022
Q4 | $1.79M | Buy |
+15,024
| New | +$1.79M | 0.51% | 48 |
|